Sanofi (SNYNF) stock
SNYNFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as SNY
$78.48−0.07 (-0.09%)
Close on Oct 19, 2026Market cap $191.40BP/E 22.1Yield –
Sanofi cash
Cash and short-term investments held at the end of each period.
Sanofi's cash was €6.35B at Jun 30, 2026. For fiscal 2025 it was €7.66B, up 2.9% from the year before. Over ten years it grew -1.8% a year on average. The highest annual figure on record is €13.92B in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €7.66B | +2.9% |
| FY2024 | Dec 31, 2024 | €7.44B | -14.6% |
| FY2023 | Dec 31, 2023 | €8.71B | -31.6% |
| FY2022 | Dec 31, 2022 | €12.74B | +26.1% |
| FY2021 | Dec 31, 2021 | €10.10B | -27.4% |
| FY2020 | Dec 31, 2020 | €13.92B | +47.6% |
| FY2019 | Dec 31, 2019 | €9.43B | +36.1% |
| FY2018 | Dec 31, 2018 | €6.93B | -32.9% |
| FY2017 | Dec 31, 2017 | €10.32B | +0.4% |
| FY2016 | Dec 31, 2016 | €10.27B | +12.3% |
| FY2015 | Dec 31, 2015 | €9.15B | +24.6% |
| FY2014 | Dec 31, 2014 | €7.34B | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | €6.35B | -6.5% |
| Q4 FY2025 | Dec 31, 2025 | €7.66B | -12.1% |
| Q2 FY2025 | Jun 30, 2025 | €15.36B | +92.2% |
| Q4 FY2024 | Dec 31, 2024 | €7.44B | -41.6% |
| Q2 FY2024 | Jun 30, 2024 | €6.80B | -1.5% |
| Q4 FY2023 | Dec 31, 2023 | €8.71B | -13.7% |
| Q2 FY2023 | Jun 30, 2023 | €7.99B | -17.8% |
| Q4 FY2022 | Dec 31, 2022 | €12.74B | -8.5% |
| Q2 FY2022 | Jun 30, 2022 | €6.90B | -56.8% |
| Q4 FY2021 | Dec 31, 2021 | €10.10B | +7.1% |
| Q2 FY2021 | Jun 30, 2021 | €9.72B | +44.2% |
| Q4 FY2020 | Dec 31, 2020 | €13.92B | +100.9% |
| Q2 FY2020 | Jun 30, 2020 | €15.97B | +54.8% |
| Q4 FY2019 | Dec 31, 2019 | €9.43B | -8.2% |
| Q2 FY2019 | Jun 30, 2019 | €6.74B | -26.3% |
| Q4 FY2018 | Dec 31, 2018 | €6.93B | -5.7% |
| Q4 FY2017 | Dec 31, 2017 | €10.32B | – |
| Q4 FY2016 | Dec 31, 2016 | €10.27B | – |
| Q4 FY2015 | Dec 31, 2015 | €9.15B | – |
| Q4 FY2014 | Dec 31, 2014 | €7.34B | – |
See a number that looks wrong?